An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

ClinicalTrials.gov ID: NCT00694109

Public ClinicalTrials.gov record NCT00694109. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Study identification

NCT ID: NCT00694109
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Kastle Therapeutics, LLC; Industry
Enrollment: 144 participants

Conditions and interventions

Conditions

Interventions

Mipomersen Sodium Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2008
Primary completion: Aug 31, 2014
Completion: Aug 31, 2014
Last update posted: Sep 8, 2016

2008 – 2014

United States locations

U.S. sites: 20
U.S. states: 16
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Mission Viejo	California	92691	—
Not listed	Newport Beach	California	92660	—
Not listed	Bridgeport	Connecticut	06606	—
Not listed	Melbourne	Florida	32901	—
Not listed	Winter Park	Florida	32792	—
Not listed	Chicago	Illinois	60654	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Biddeford	Maine	04005	—
Not listed	Boston	Massachusetts	02114	—
Not listed	St Louis	Missouri	63110	—
Not listed	Concord	New Hampshire	03301	—
Not listed	New York	New York	10032	—
Not listed	Charlotte	North Carolina	28204	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cincinnati	Ohio	45212	—
Not listed	Franklin	Ohio	45005	—
Not listed	Portland	Oregon	97239	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Dallas	Texas	75226	—
Not listed	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00694109, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 8, 2016 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00694109 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →